title: Clinical Trial of Erythropoietin in Young Children With Cerebral Palsy.
abstract: This study was conducted to assess the safety and efficacy of recombinant human erythropoietin in young children with cerebral palsy aged between 6 months and 3 years. All participants received subcutaneous recombinant human erythropoietin and 8 weeks of rehabilitation therapy. Adverse events, changes of vital signs, and hematologic tests were monitored up to 8 weeks postinjection. Functional measures of development at 4 and 8 weeks postinjection were compared with baseline values, and improvements were compared with those of an age-matched historical control group. Nine participants completed the trial from June 2012 to February 2015. No adverse events were related to recombinant human erythropoietin. Erythropoiesis was noted, although within normal range. Functional improvements were observed in all participants (P < .05) and increases in motor function were higher in recombinant human erythropoietin group than the control group. Accordingly, recombinant human erythropoietin administration was safe without any significant adverse events and improved the functional outcomes in young children with cerebral palsy.
authors.affiliation: Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University, Gyeonggi-do, Republic of Korea.
authors.forename: Kye Hee
authors.initials: KH
authors.lastname: Cho
authors.affiliation: Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University, Gyeonggi-do, Republic of Korea.
authors.forename: Kyunghoon
authors.initials: K
authors.lastname: Min
authors.affiliation: Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University, Gyeonggi-do, Republic of Korea.
authors.forename: Seung Hoon
authors.initials: SH
authors.lastname: Lee
authors.affiliation: Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University, Gyeonggi-do, Republic of Korea.
authors.forename: SunHee
authors.initials: S
authors.lastname: Lee
authors.affiliation: Department of Bionanotechnology and Gachon Medical Research Institute, Gachon University, Gyeonggi-do, Republic of Korea.
authors.forename: SeongSoo A
authors.initials: SA
authors.lastname: An
authors.affiliation: Department of Rehabilitation Medicine, CHA Bundang Medical Center, CHA University, Gyeonggi-do, Republic of Korea kmin@cha.ac.kr.
authors.forename: MinYoung
authors.initials: M
authors.lastname: Kim
mesh_terms: D002547:Cerebral Palsy / Q000188:drug therapy* / Q000534:rehabilitation; D002675:Child, Preschool; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007279:Injections, Subcutaneous; D008297:Male; D009465:Neuromuscular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: C554270:EPO protein, human; D009465:Neuromuscular Agents; D011994:Recombinant Proteins; D004921:Erythropoietin
keywords: cerebral palsy; efficacy; erythropoietin; safety; therapy